Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeted sequencing reveals the mutational landscape responsible for sorafenib therapy in advanced hepatocellular carcinoma.

Theranostics - 1 Jan 2020

Tang Jing, Sui Cheng-Jun, Wang Dong-Fang, Lu Xin-Yuan, Luo Gui-Juan, Zhao Qing, Lian Qiu-Yu, Jeong Seogsong, Lin Xi-Meng, Zhu Yan-Jing, Zheng Bo, Wu Rui, Wang Qing, Liu Xiao-Long, Liu Jing-Feng, Xia Qiang, Wu Gang, Gu Jin, Wang Hong-Yang, Chen Lei

Abstract excerpt

Rationale: The existence of primary and acquired drug resistance is the main obstacle for the effect of multi-kinase inhibitor sorafenib and regorafenib in advanced hepatocellular carcinoma (HCC). However, plenty of patients did not significantly benefit from sorafenib treatment and little is known about the mechanism of drug resistance. Methods: Laser capture microdissection was used to acquire matched normal...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinoma, Hepatocellular

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Liver Neoplasms

Share to Octamer Transcription Factor-3

Share to Phenylurea Compounds

Share to Pyridines

Share to Sorafenib

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 32373219
DOI: 10.7150/thno.41616
PMCID: PMC7196302

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeted sequencing reveals the mutational landscape responsible for sorafenib therapy in advanced hepatocellular carcinoma.PMID 32373219Read ↗

Sorafenib Resistance in Hepatocellular Carcinoma: The Relevance of Genetic HeterogeneitySemantic proximity Read ↗

SLC15A2 genomic variation is associated with the extraordinary response of sorafenib treatment: whole-genome analysis in patients with hepatocellular carcinoma.Semantic proximity Read ↗

TP53 and RET may serve as biomarkers of prognostic evaluation and targeted therapy in hepatocellular carcinoma.Semantic proximity Read ↗

Advances in targeted therapies for hepatocellular carcinoma in the genomic era.Semantic proximity Read ↗

Analysis of genetic mutation characteristics in 40 Chinese patients with hepatocellular carcinoma.Semantic proximity Read ↗

Multi-omics of sorafenib responsiveness in HCC patientsSemantic proximity Read ↗

Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib.Semantic proximity Read ↗

Differences in somatic mutation landscape of hepatocellular carcinoma in Asian American and European American populations.Semantic proximity Read ↗

Targeted and exome sequencing identified somatic mutations in hepatocellular carcinomaSemantic proximity Read ↗

Targeted DNA and RNA sequencing of fine-needle biopsy FFPE specimens in patients with unresectable hepatocellular carcinoma treated with sorafenib.Semantic proximity Read ↗

ITGA5 and ITGB1 contribute to Sorafenib resistance by promoting vasculogenic mimicry formation in hepatocellular carcinomaSemantic proximity Read ↗

Rs9679162 genotype predicts prognosis of real-world advanced hepatocellular carcinoma treated by sorafenib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.